Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Registrational; Therapeutic Use
- Acronyms BRAVE II; SLE-BRAVE-II
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 08 Mar 2024 This study has been completed in Italy, according to European Clinical Trials Database record.
- 24 Feb 2023 Status changed to completed, as per results published in the Lancet.
- 24 Feb 2023 Results (n=775) assessing the efficacy and safety of baricitinib in patients with systemic lupus erythematosus in a 52-week phase 3 study, published in the Lancet.